Navigation Links
Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
Date:10/14/2008

best-in-class product with favorable hemodynamic and renal activity," said Peter Strumph, Chief Executive Officer of Nile. "We believe that the results from this patient population will be predictive of activity in our upcoming Phase 2b study in acute heart failure patients. We look forward to announcing the full results from this Phase 2a study, as well as results from the ongoing phase 1b study in stable heart failure patients."

Information regarding this study is available at the U.S. government's clinical trials database at http://www.clinicaltrials.gov.

About Heart Failure

Heart failure (HF) is a chronic condition in which the heart cannot effectively pump enough blood to the body's other organs, either as a result of impaired contractility (systolic heart failure) or impaired relaxation and ventricular filling (diastolic heart failure). HF is a major and growing public health problem affecting 5.3 million Americans, with over 650,000 new cases diagnosed every year. The annual mortality rate for heart failure is 19%. Treatment of Heart Failure generates annual costs of approximately $35 billion, of which approximately $3 billion is spent on drugs and $19 billion is spent in the acute hospital setting. Heart Failure patients frequently suffer episodes of acute decompensated heart failure (ADHF) which require hospitalization. For Americans over 65 years of age, ADHF is the most frequent cause of hospital admission. In recent years, 2.4 million patients in the US were hospitalized with a primary or secondary discharge code of ADHF with an average hospital stay of 4.3 days.

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of ADHF. CD-NP was rationally designed by scientists at the Mayo Clinic's Cardiorenal Research Labs. Current therapies for ADHF, including B-type natriuretic peptide, have been associated with favorable p
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... July 28, 2014 Immunomic Therapeutics, Inc. ... to further develop potential treatments for glioblastoma multiforme (GBM), ... combination with their patented vaccine platform, LAMP-vax. , ... are based on the work of John H. Sampson, ... The Preston Robert Tisch Brain Tumor Center at Duke ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3
... Jan. 11, 2011 SeqWright Inc., a world-wide ... continues to make significant strides to position itself ... 2011. SeqWright,s ongoing success can be attributed to ... demands and by investing in key genomics technologies. ...
... and NASHVILLE, Tenn., Jan. 11, 2011 AstraZeneca (NYSE: ... (SCRI), an international leader in advancing therapies for cancer ... lead the clinical development of a novel targeted oncology ... major cause of mortality globally; accounting for 7.4 million ...
... York, NY, 10 January 2011 Elsevier ... Diamond, Diamond-Like Materials, Carbon Nanotubes and Nitrides, will occur ... Elsevier organized conference discusses the significant improvements in material ... over the past few years. The improvements have lead ...
Cached Biology Technology:SeqWright Continues Expansion of Next-Generation Sequencing Capabilities 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 3
(Date:7/28/2014)... prevent and treat HIV infection has been problematic until ... can arouse as they get rid of the invaders. ... Institute and the National Institutes of Health (NIH) have ... interferons around the time of infection could have ... research appeared in Nature . , Interferons, ...
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... global climate change to cut food supplies. But these ... between increasing temperature and air pollution specifically ozone ... new study involving researchers at MIT shows that these ... to take both warming and air pollution into account ... detail at global production of four leading food crops ...
Breaking Biology News(10 mins):Interfering with interferon 2Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... BOSTON--Scientists at Dana-Farber Cancer Institute have uncovered the mechanism ... cancer cells, DNA with potent drugs while simultaneously preventing ... reported in the Aug. 14 issue of Molecular ... in clinical trials of compounds that force cancer cells ...
... toxin in an amphibian a 60 amino acid neurotoxin found ... may help shed more light into both the evolution of ... protein toxins have been identified in many vertebrate animals, including ... amphibians or birds. In the case of poisonous amphibians, like ...
... San Antonio Tao Weitao, a researcher in the College ... at San Antonio is making great strides in a project ... Area Foundation. The professor in the South Texas Center ... a soil-dwelling bacterium that threatens the health of military personnel ...
Cached Biology News:Study supports DNA repair-blocker research in cancer therapy 2Study supports DNA repair-blocker research in cancer therapy 3UTSA biology researchers demystify elusive war zone bacterium 2
... operate as a Voltage Clamp, as a Current ... electrophysiology research applications. Performance in any one mode ... • This amazing instrument is ... capabilities of Digital Signal Processing (DSP) integrated circuit ...
... Identical to the DH-2000, but comes with ... switch up to 5 Hz) The ... the continuous spectrum of deuterium and tungsten halogen ... combined-spectrum light source produces a powerful, stable output ...
... in g per ml and is determined from ... of a 1 mg per ml solution. ... agglutinate a 2% suspension of human blood group ... C. Preparation Note: Affinity purified by ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
Biology Products: